Outcomes Following Adalimumab Bio-originator to Biosimilar Switch-A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries.
Peter C TaylorYuri Sanchez GonzalezRyan ClarkFreddy FaccinOliver HowellPublished in: Rheumatology and therapy (2023)
Non-medical switching in RA treatment may lead to unforeseen outcomes that should be considered by health decision-makers.
Keyphrases
- healthcare
- rheumatoid arthritis
- public health
- primary care
- emergency department
- case report
- mental health
- electronic health record
- disease activity
- decision making
- type diabetes
- health information
- ankylosing spondylitis
- adipose tissue
- machine learning
- insulin resistance
- risk assessment
- systemic sclerosis
- human health
- replacement therapy
- climate change
- hidradenitis suppurativa
- weight loss
- glycemic control